JP2020529835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529835A5 JP2020529835A5 JP2019571685A JP2019571685A JP2020529835A5 JP 2020529835 A5 JP2020529835 A5 JP 2020529835A5 JP 2019571685 A JP2019571685 A JP 2019571685A JP 2019571685 A JP2019571685 A JP 2019571685A JP 2020529835 A5 JP2020529835 A5 JP 2020529835A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- antigen
- group
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 65
- 108091000831 antigen binding proteins Proteins 0.000 claims description 65
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 50
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 241000701806 Human papillomavirus Species 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 18
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 7
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000012642 immune effector Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 4
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 210000004392 genitalia Anatomy 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 238000007422 luminescence assay Methods 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 201000006958 oropharynx cancer Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 229960002566 papillomavirus vaccine Drugs 0.000 claims description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 11
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004085 squamous epithelial cell Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023206822A JP7737440B2 (ja) | 2017-06-28 | 2023-12-07 | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762525937P | 2017-06-28 | 2017-06-28 | |
| US62/525,937 | 2017-06-28 | ||
| PCT/US2018/039654 WO2019005897A1 (en) | 2017-06-28 | 2018-06-27 | HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023206822A Division JP7737440B2 (ja) | 2017-06-28 | 2023-12-07 | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529835A JP2020529835A (ja) | 2020-10-15 |
| JP2020529835A5 true JP2020529835A5 (enExample) | 2021-07-26 |
| JP7401312B2 JP7401312B2 (ja) | 2023-12-19 |
Family
ID=63080480
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571685A Active JP7401312B2 (ja) | 2017-06-28 | 2018-06-27 | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 |
| JP2023206822A Active JP7737440B2 (ja) | 2017-06-28 | 2023-12-07 | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023206822A Active JP7737440B2 (ja) | 2017-06-28 | 2023-12-07 | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10806780B2 (enExample) |
| EP (1) | EP3645562A1 (enExample) |
| JP (2) | JP7401312B2 (enExample) |
| KR (2) | KR102702859B1 (enExample) |
| CN (2) | CN118978585A (enExample) |
| AU (1) | AU2018290856B2 (enExample) |
| BR (1) | BR112019027211A2 (enExample) |
| CA (1) | CA3066779A1 (enExample) |
| CL (3) | CL2019003802A1 (enExample) |
| CO (1) | CO2020000733A2 (enExample) |
| EA (1) | EA202090149A1 (enExample) |
| IL (3) | IL299348B2 (enExample) |
| MA (1) | MA49512A (enExample) |
| MX (2) | MX2019015477A (enExample) |
| MY (1) | MY200131A (enExample) |
| PH (1) | PH12019502763A1 (enExample) |
| SG (1) | SG11201912240QA (enExample) |
| WO (1) | WO2019005897A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299348B2 (en) | 2017-06-28 | 2025-05-01 | Regeneron Pharma | Antigen-binding proteins against human papillomavirus and methods of using them |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| CN112566698A (zh) | 2018-04-05 | 2021-03-26 | 朱诺治疗学股份有限公司 | T细胞受体和表达该t细胞受体的工程化细胞 |
| JP7674278B2 (ja) * | 2019-07-03 | 2025-05-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法 |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| HUE062777T2 (hu) | 2020-02-26 | 2023-12-28 | Vir Biotechnology Inc | SARS-CoV-2 elleni antitestek |
| CN111410689B (zh) * | 2020-03-16 | 2021-11-02 | 重庆理工大学 | 抗hpv16e7蛋白单抗69e2、杂交瘤细胞株及其制备方法和应用 |
| CN111333720B (zh) * | 2020-03-16 | 2021-11-02 | 重庆理工大学 | 抗hpv16e7蛋白单抗79a11、杂交瘤细胞株及其制备方法和应用 |
| WO2021226063A1 (en) * | 2020-05-05 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Car comprising cd28 zeta and cd3 zeta |
| CN112433055A (zh) * | 2020-11-04 | 2021-03-02 | 上海药明生物技术有限公司 | 一种基于报告基因方法检测pvrig抗体的生物学活性的方法 |
| CN112480217B (zh) * | 2020-11-30 | 2022-04-08 | 广州阿格纳生物医药制造有限公司 | 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物 |
| CN114957452B (zh) * | 2021-02-18 | 2025-08-08 | 江苏瑞科生物技术股份有限公司 | 一种人乳头瘤病毒11型l1蛋白的抗体及其制备方法 |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| CA3229369A1 (en) | 2021-08-16 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Novel il27 receptor agonists and methods of use thereof |
| WO2023133193A1 (en) * | 2022-01-05 | 2023-07-13 | Memorial Sloan-Kettering Cancer Center | Anti-hpv antibodies and uses thereof |
| KR20240163103A (ko) * | 2022-03-10 | 2024-11-18 | 주식회사 제넥신 | 두경부암 치료를 위한 삼중 복합약물 투여요법 |
| AU2024207005A1 (en) | 2023-01-13 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| IL322890A (en) | 2023-02-28 | 2025-10-01 | Regeneron Pharma | Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen |
| CN118725049A (zh) * | 2024-06-28 | 2024-10-01 | 宁波君健生物科技有限公司 | 自复制mRNA序列及其在制备抗HPV肿瘤药物中的用途 |
| WO2026050587A1 (en) * | 2024-08-30 | 2026-03-05 | Obi Pharma, Inc. | Novel anti-nectin-4 antibodies, conjugated biological molecules, pharmaceutical compositions and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| DE3681787D1 (de) | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| HK1008049A1 (en) | 1987-09-11 | 1999-04-30 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and use therefor |
| ATE110108T1 (de) | 1987-12-11 | 1994-09-15 | Whitehead Biomedical Inst | Genetische modifizierung von endothelialen zellen. |
| DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
| US5180806A (en) | 1988-05-16 | 1993-01-19 | The Scripps Research Institute | Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods |
| CA2038581A1 (en) | 1990-03-20 | 1991-09-21 | Martin Muller | Seroreactive epitopes of human papillomavirus (hpv) 16 proteins |
| AU8762991A (en) * | 1990-09-26 | 1992-04-15 | Bristol-Myers Squibb Company | Human papilloma viral protein expression for use in vaccine compositions |
| DE69123981T3 (de) | 1990-10-31 | 2006-06-14 | Cell Genesys Inc | Nützliche retrovirale vektoren für die gentherapie |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002077012A2 (en) * | 2001-03-23 | 2002-10-03 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Human papilloma virus immunoreative peptides |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| CO5770113A1 (es) * | 2006-04-28 | 2007-06-29 | Fundacion Inst De Inmunologia De Colombia | Peptidos para detectar o inducir la produccion de anticuerpos anti el virus de pailoma humano, anti la proteina l1 o anti peptidos de esta proteina |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| JP5707326B2 (ja) * | 2008-09-02 | 2015-04-30 | アンティジェン・エクスプレス・インコーポレーテッドＡｎｔｉｇｅｎ Ｅｘｐｒｅｓｓ，Ｉｎｃ． | ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法 |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| CN102443060B (zh) | 2010-10-13 | 2014-04-30 | 上海泽润生物科技有限公司 | 一种抗hpv的抗体、其制备方法和应用 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EA201401134A1 (ru) | 2011-02-11 | 2015-05-29 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Hla-рестиктированные пептидоспецифические антигенсвязывающие белки |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2567972A1 (en) * | 2011-09-12 | 2013-03-13 | Adriacell S.p.A. | Antibodies against E7 protein of Human Papilloma Virus (HPV) |
| CN102719402B (zh) | 2012-07-05 | 2014-05-14 | 时宏珍 | Hla-a0201限制性抗hpv抗原特异性ctl的制备方法 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN110511960B (zh) | 2013-07-15 | 2023-05-23 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e6 t细胞受体 |
| EP2883550A1 (en) * | 2013-12-12 | 2015-06-17 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Novel promiscuous HPV16-derived T helper epitopes for immunotherapy |
| EP3097117B1 (en) * | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| PT3149031T (pt) * | 2014-05-29 | 2020-03-25 | Us Health | Receptores de células t anti-e7 do papilomavírus humano 16 |
| RU2756247C2 (ru) | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| JP2018516879A (ja) | 2015-05-08 | 2018-06-28 | ユーリカ セラピューティックス， インコーポレイテッド | Ｈｐｖ１６−ｅ７ペプチド／ｍｈｃ複合体を標的化する構築物およびその使用 |
| CN105131113B (zh) * | 2015-08-26 | 2019-09-06 | 艾托金生物医药（苏州）有限公司 | 用于宫颈癌检测和分级的单隆抗体及其应用 |
| EP3156067A1 (en) * | 2015-10-16 | 2017-04-19 | Max-Delbrück-Centrum Für Molekulare Medizin | High avidity hpv t-cell receptors |
| KR20190062505A (ko) * | 2016-10-03 | 2019-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
| IL299348B2 (en) | 2017-06-28 | 2025-05-01 | Regeneron Pharma | Antigen-binding proteins against human papillomavirus and methods of using them |
-
2018
- 2018-06-27 IL IL299348A patent/IL299348B2/en unknown
- 2018-06-27 MY MYPI2019007368A patent/MY200131A/en unknown
- 2018-06-27 JP JP2019571685A patent/JP7401312B2/ja active Active
- 2018-06-27 EA EA202090149A patent/EA202090149A1/ru unknown
- 2018-06-27 CA CA3066779A patent/CA3066779A1/en active Pending
- 2018-06-27 AU AU2018290856A patent/AU2018290856B2/en active Active
- 2018-06-27 SG SG11201912240QA patent/SG11201912240QA/en unknown
- 2018-06-27 IL IL317281A patent/IL317281A/en unknown
- 2018-06-27 MA MA049512A patent/MA49512A/fr unknown
- 2018-06-27 MX MX2019015477A patent/MX2019015477A/es unknown
- 2018-06-27 US US16/019,703 patent/US10806780B2/en active Active
- 2018-06-27 KR KR1020207002440A patent/KR102702859B1/ko active Active
- 2018-06-27 BR BR112019027211-9A patent/BR112019027211A2/pt unknown
- 2018-06-27 WO PCT/US2018/039654 patent/WO2019005897A1/en not_active Ceased
- 2018-06-27 KR KR1020247029312A patent/KR102877389B1/ko active Active
- 2018-06-27 CN CN202410994510.9A patent/CN118978585A/zh active Pending
- 2018-06-27 CN CN201880044309.7A patent/CN110914295B/zh active Active
- 2018-06-27 EP EP18749628.6A patent/EP3645562A1/en active Pending
-
2019
- 2019-12-05 PH PH12019502763A patent/PH12019502763A1/en unknown
- 2019-12-06 IL IL271231A patent/IL271231B2/en unknown
- 2019-12-18 MX MX2024002706A patent/MX2024002706A/es unknown
- 2019-12-20 CL CL2019003802A patent/CL2019003802A1/es unknown
-
2020
- 2020-01-23 CO CONC2020/0000733A patent/CO2020000733A2/es unknown
- 2020-08-13 US US16/992,188 patent/US11559576B2/en active Active
-
2021
- 2021-12-16 CL CL2021003368A patent/CL2021003368A1/es unknown
-
2022
- 2022-12-15 US US18/081,782 patent/US12115216B2/en active Active
-
2023
- 2023-12-07 JP JP2023206822A patent/JP7737440B2/ja active Active
-
2024
- 2024-06-27 CL CL2024001977A patent/CL2024001977A1/es unknown
- 2024-09-11 US US18/830,643 patent/US20250064913A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299348B1 (en) | Antigen-binding proteins against human papillomavirus and methods of using them | |
| AU2018312222B2 (en) | Anti-CD47 antibodies and uses thereof | |
| TWI758558B (zh) | Cd96抗體、其抗原結合片段及醫藥用途 | |
| TWI793062B (zh) | Ｄｌｌ３及ｃｄ３抗體構築體 | |
| JP6606505B2 (ja) | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 | |
| JP2020528750A5 (enExample) | ||
| JP2023027374A (ja) | 抗ｃｄ３抗体及び該抗体を含む分子 | |
| TW202144417A (zh) | Ｐｖｒｉｇ結合蛋白及其醫藥用途 | |
| TW201837174A (zh) | 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子 | |
| JP2022538475A5 (enExample) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| TW202327649A (zh) | Ｐｖｒｉｇ／ｔｉｇｉｔ結合蛋白聯合免疫檢查點抑制劑用於治療癌症 | |
| CN104662153A (zh) | 针对转运体的抗体及其用途 | |
| AU2020390028B2 (en) | Pharmaceutical composition, preparation method therefor and use thereof | |
| WO2023040945A1 (zh) | 特异性结合pd-1的蛋白及其医药用途 | |
| CN117858903A (zh) | 一种含抗pvrig/tigit双特异性抗体的药物组合物 | |
| WO2023036281A1 (zh) | 抗cd47抗体及其用途 | |
| WO2023241656A1 (zh) | 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途 | |
| WO2024175105A1 (zh) | 一种fap/cd40结合分子的药物组合物及其医药用途 | |
| WO2019076277A1 (zh) | 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 | |
| TW202313692A (zh) | 抗ｉｌ４ｒ抗體的藥物組成物及其用途 | |
| US20240384006A1 (en) | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases | |
| TW202300516A (zh) | Ｐｄ—１結合蛋白及其醫藥用途 | |
| WO2024188331A1 (zh) | 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途 | |
| KR20240072932A (ko) | B7-h3에 특이적으로 결합하는 항체 |